Tech Company Financing Transactions

FogPharma Funding Round

Arch Venture Partners, Casdin Capital and Cormorant Asset Management participated in a $178 million Series D capital raise for FogPharma. The round closed on 11/21/2022.

Transaction Overview

Company Name
Announced On
11/21/2022
Transaction Type
Venture Equity
Amount
$178,000,000
Round
Series D
Proceeds Purpose
Proceeds from the Series D financing will be used to advance and accelerate FogPharma's growing pipeline of hyperstabilized a-helical (Helicon�) polypeptide therapeutics, a proprietary new class of drugs designed to overcome the limitations of today's precision medicines with broad applicability to the vast majority of disease targets and therapeutic areas.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Acorn Park Dr.
Cambridge, MA 02140
USA
Email Address
Overview
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that 'drug the undruggable.' FogPharma's cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics.
Profile
FogPharma LinkedIn Company Profile
Social Media
FogPharma Company Twitter Account
Company News
FogPharma News
Facebook
FogPharma on Facebook
YouTube
FogPharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Gregory Verdine
  Gregory Verdine LinkedIn Profile  Gregory Verdine Twitter Account  Gregory Verdine News  Gregory Verdine on Facebook
Chief Financial Officer
Tony Gibney
  Tony Gibney LinkedIn Profile  Tony Gibney Twitter Account  Tony Gibney News  Tony Gibney on Facebook
Chief Operating Officer
WeiQing Zhou
  WeiQing Zhou LinkedIn Profile  WeiQing Zhou Twitter Account  WeiQing Zhou News  WeiQing Zhou on Facebook
Chief Scientific Officer
Howard Stern
  Howard Stern LinkedIn Profile  Howard Stern Twitter Account  Howard Stern News  Howard Stern on Facebook
Vice President
Jonathan Hurov
  Jonathan Hurov LinkedIn Profile  Jonathan Hurov Twitter Account  Jonathan Hurov News  Jonathan Hurov on Facebook
Vice President
Martin Tremblay
  Martin Tremblay LinkedIn Profile  Martin Tremblay Twitter Account  Martin Tremblay News  Martin Tremblay on Facebook
VP - Finance
Stephen Fair
  Stephen Fair LinkedIn Profile  Stephen Fair Twitter Account  Stephen Fair News  Stephen Fair on Facebook
VP - Human Resources
Sandra Smith
  Sandra Smith LinkedIn Profile  Sandra Smith Twitter Account  Sandra Smith News  Sandra Smith on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/21/2022: Green Shield Risk Solutions venture capital transaction
Next: 11/21/2022: Surround Insurance venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary